Matthew Beacom, MD
Family Medicine · Fremont, NENPI 1568476679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations.
Across 151 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$336
- Lilly USA, LLC$300
- Novartis$219
- Pfizer$191
- Harmony Biosciences LLC$165
- Actelion Pharmaceuticals US, Inc.$122
- plus $1K from 24 others
Across 90 payments — averaging $1084.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$49K
- Romark Laboratories, LC$48K
- Janssen Research & Development, LLC$938
- GSK$137
What the payments were for
- Food & beverage$2,30694%
- Education$1476%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $336 |
| Lilly USA, LLC | 20 | $300 |
| Novartis | 15 | $219 |
| Pfizer | 12 | $191 |
| Harmony Biosciences LLC | 12 | $165 |
| Actelion Pharmaceuticals US, Inc. | 2 | $122 |
| Johnson & Johnson | 5 | $103 |
| Sumitomo Pharma America, Inc. | 5 | $103 |
| AbbVie | 6 | $92 |
| Idorsia Pharmaceuticals US Inc | 4 | $69 |
| Bayer | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 5 | $66 |
| Collegium Pharmaceutical, Inc. | 3 | $58 |
| Boehringer Ingelheim | 4 | $57 |
| AstraZeneca | 4 | $53 |
| Genentech USA, Inc. | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 3 | $43 |
| GSK | 3 | $41 |
| Mylan Specialty L.p. | 2 | $38 |
| Biogen | 2 | $36 |
| Exact Sciences | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Seqirus USA Inc | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,453 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 250 | $90,251 |
| OzempicSemaglutide | 34 | $37,341 |
| XareltoRivaroxaban | 69 | $36,879 |
| JardianceEmpagliflozin | 73 | $31,371 |
| MounjaroTirzepatide | 26 | $27,081 |
| FarxigaDapagliflozin Propanediol | 24 | $20,119 |
| Sildenafil Citrate | 24 | $19,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $17,650 |
| MyrbetriqMirabegron | 45 | $13,812 |
| GemtesaVibegron | 37 | $11,776 |
| JanuviaSitagliptin Phosphate | 13 | $9,524 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $8,325 |
| EntrestoSacubitril/Valsartan | 14 | $7,438 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 20 | $6,276 |
| Atorvastatin Calcium | 384 | $5,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $191 | $90,251250 claims |
| Novo NordiskOzempic | $336 | $37,34134 claims |
| Johnson & JohnsonXarelto | $103 | $36,87969 claims |
| Boehringer IngelheimJardiance, Tradjenta | $57 | $34,53985 claims |
| GSKTrelegy Ellipta, Arexvy, Incruse Ellipta, Shingrix | $41 | $32,27181 claims |
| Lilly USA, LLCMounjaro | $300 | $27,08126 claims |
| AstraZenecaFarxiga | $53 | $20,11924 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $103 | $11,77637 claims |
| NovartisEntresto | $219 | $7,43814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Fremont
- Andrea VermaasFremont$11K
- Michael IsraelLincoln$375K
- Francisco DozonNorfolk$238K
- Randy KohlLincoln$67K
- James OmelGrand Island$67K
- Gerard StanleyOmaha$50K
- Jared KramerSt Paul$41K
- Randolph WaldmanHebron$27K
- Brian FinleyBellevue$20K
- William FitzgibbonsElkhorn$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.